4th Obesity & Weight Loss Drug Development Summit

Welcome to the 4th Obesity & Weight Loss Drug Development Summit – the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment, preserving functional health, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies.

The obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins, the landscape has reached a critical juncture where “simple weight loss” is no longer enough to win. As we move through 2026, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free, scalable solutions that promise to transform chronic disease management forever.

The 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year, we are diving deep into the game-changing potential of multi-targeted portfolios, novel biological pathways and new modalities for a precision medicine approach, alongside the “Oral-First” revolution.

Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Merck & Co., as well as innovative biotechs such as Veru Inc., Canary Cure, and Metsera, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain.

Don’t miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline.

View the full event guide: https://ter.li/p453jn